Literature DB >> 4974996

Inhibition of release of vaccinia virus by N1-isonicotinoly-N2-3-methyl-4-chlorobenzoylhydrazine.

N Kato, H J Eggers, H Rolly.   

Abstract

N(1)-isonicotinoyl-N(2)-3-methyl-4-chlorobenzoylhydrazine (IMCBH) is a selective inhibitor of vaccinia virus multiplication. In concentrations up to 50 microg/ml, IMCBH causes neither toxic morphologic changes, nor does it inhibit the multiplication of cells. Viruses other than vaccinia are not affected by IMCBH. The virus-inhibitory effect of IMCBH is dependent on the type of host cell used, i.e., the compound is effective in chick embryo fibroblasts and monkey kidney cells but not in L cells. IMCBH does not exhibit any protecting effect on vaccinia virus-infected mice or rabbits. IMCBH interferes with virus release: in single cycle experiments in chick embryo fibroblasts, IMCBH strongly blocks the release of vaccinia virus at concentrations as low as 3 microg/ml, while intracellular virus synthesis is hardly affected. Viral cytopathic changes are completely suppressed by IMCBH within the span of a single cycle infection, although extensive changes eventually occur. By inhibiting virus release from initially infected cells, IMCBH markedly inhibits the multiplication of vaccinia virus in cell cultures infected at low virus/ cell multiplicities. IMCBH does not inhibit the early toxic cytopathic changes induced by large inocula of vaccinia virus in BHK21 cells.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4974996      PMCID: PMC2138633          DOI: 10.1084/jem.129.4.795

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  Amino acid metabolism in mammalian cell cultures.

Authors:  H EAGLE
Journal:  Science       Date:  1959-08-21       Impact factor: 47.728

2.  THE CYCLE OF MULTIPLICATION OF VACCINIA VIRUS IN EARLE'S STRAIN L CELLS. I. UPTAKE AND PENETRATION.

Authors:  S DALES; R KAJIOKA
Journal:  Virology       Date:  1964-11       Impact factor: 3.616

3.  The toxic activity of vaccinia virus in tissue culture.

Authors:  A BROWN; S A MAYYASI; J E OFFICER
Journal:  J Infect Dis       Date:  1959 Mar-Apr       Impact factor: 5.226

4.  The toxic effect of vaccinia virus on leucocytes in vitro.

Authors:  M NISHMI; H BERNKOPF
Journal:  J Immunol       Date:  1958-12       Impact factor: 5.422

5.  [Agglutination of a pure strain of mammalian cells (L strain, Earle) by suspensions of vaccina virus].

Authors:  W F SCHERER
Journal:  Proc Soc Exp Biol Med       Date:  1952 Aug-Sep

6.  The effect of azo dyes on myxovirus neuraminidase and on virus multiplication.

Authors:  H Becht; R Drzeniek
Journal:  J Gen Virol       Date:  1968-03       Impact factor: 3.891

7.  Plaque formation and isolation of pure lines with poliomyelitis viruses.

Authors:  R DULBECCO; M VOGT
Journal:  J Exp Med       Date:  1954-02       Impact factor: 14.307

8.  Spectrum and characteristics of the virus inhibitory action of 2-(alpha-hydroxybenzyl)-benzimidazole.

Authors:  H J EGGERS; I TAMM
Journal:  J Exp Med       Date:  1961-04-01       Impact factor: 14.307

9.  Growth characteristics of influenza virus; biochemical differentiation of stages of development.

Authors:  W W ACKERMANN; H F MAASSAB
Journal:  J Exp Med       Date:  1954-10-01       Impact factor: 14.307

10.  Growth characteristics of influenza virus: the influence of a sulfonic acid.

Authors:  W W ACKERMANN; H F MAASSAB
Journal:  J Exp Med       Date:  1954-02       Impact factor: 14.307

View more
  14 in total

1.  Extracellular vaccinia virus formation and cell-to-cell virus transmission are prevented by deletion of the gene encoding the 37,000-Dalton outer envelope protein.

Authors:  R Blasco; B Moss
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

Review 2.  Phospholipase D: enzymology, functionality, and chemical modulation.

Authors:  Paige E Selvy; Robert R Lavieri; Craig W Lindsley; H Alex Brown
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

3.  Retrograde Transport from Early Endosomes to the trans-Golgi Network Enables Membrane Wrapping and Egress of Vaccinia Virus Virions.

Authors:  Gilad Sivan; Andrea S Weisberg; Jeffrey L Americo; Bernard Moss
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

Review 4.  Orthopoxvirus targets for the development of antiviral therapies.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Curr Drug Targets Infect Disord       Date:  2005-03

5.  Reactivation of transcription from a vaccinia virus early promoter late in infection.

Authors:  J Garcés; K Masternak; B Kunz; R Wittek
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

6.  A mutation in the gene encoding the vaccinia virus 37,000-M(r) protein confers resistance to an inhibitor of virus envelopment and release.

Authors:  C Schmutz; L G Payne; J Gubser; R Wittek
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

7.  Characterization of intracellular and extracellular vaccinia virus variants: N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine interferes with cytoplasmic virus dissemination and release.

Authors:  G Hiller; H Eibl; K Weber
Journal:  J Virol       Date:  1981-09       Impact factor: 5.103

8.  Effect of glycosylation inhibitors on the release of enveloped vaccinia virus.

Authors:  L G Payne; K Kristensson
Journal:  J Virol       Date:  1982-02       Impact factor: 5.103

9.  Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment.

Authors:  G Hiller; K Weber
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

10.  Mechanism of vaccinia virus release and its specific inhibition by N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine.

Authors:  L G Payne; K Kristenson
Journal:  J Virol       Date:  1979-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.